Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMM60 |
| Synonyms | |
| Therapy Description |
IMM60 is a synthetic agonist of invariant natural killer T-cells (iNKT) encapsulated in liposomes, which potentially increases antitumor immune response and decreases tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMM60 | IMM-60|IMM 60 | IMM60 is a synthetic agonist of invariant natural killer T-cells (iNKT) encapsulated in liposomes, which potentially increases antitumor immune response and decreases tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |